Product Surveillance, Postmarketing
"Product Surveillance, Postmarketing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
Concept/Terms
Product Surveillance, Postmarketing- Product Surveillance, Postmarketing
- Product Surveillance, Post-Marketing
- Post-Marketing Product Surveillance
- Post-Marketing Product Surveillances
- Product Surveillance, Post Marketing
- Product Surveillances, Post-Marketing
- Surveillance, Post-Marketing Product
- Surveillances, Post-Marketing Product
- Evaluation Studies, Postmarketing
- Evaluation Study, Postmarketing
- Postmarketing Evaluation Studies
- Postmarketing Evaluation Study
- Studies, Postmarketing Evaluation
- Study, Postmarketing Evaluation
- Postmarketing Product Surveillance
- Postmarketing Product Surveillances
- Product Surveillances, Postmarketing
- Surveillance, Postmarketing Product
- Surveillances, Postmarketing Product
Drug Surveillance, Postmarketing- Drug Surveillance, Postmarketing
- Drug Surveillances, Postmarketing
- Postmarketing Drug Surveillance
- Postmarketing Drug Surveillances
- Surveillance, Postmarketing Drug
- Surveillances, Postmarketing Drug
Below are MeSH descriptors whose meaning is more general than "Product Surveillance, Postmarketing".
Below are MeSH descriptors whose meaning is more specific than "Product Surveillance, Postmarketing".
This graph shows the total number of publications written about "Product Surveillance, Postmarketing" by people in Harvard Catalyst Profiles by year, and whether "Product Surveillance, Postmarketing" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 0 | 1 | 1 |
1996 | 1 | 2 | 3 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 1 | 2 |
2002 | 2 | 1 | 3 |
2003 | 1 | 4 | 5 |
2004 | 1 | 0 | 1 |
2005 | 4 | 5 | 9 |
2006 | 3 | 2 | 5 |
2007 | 4 | 5 | 9 |
2008 | 5 | 5 | 10 |
2009 | 7 | 5 | 12 |
2010 | 4 | 5 | 9 |
2011 | 7 | 7 | 14 |
2012 | 17 | 9 | 26 |
2013 | 18 | 13 | 31 |
2014 | 16 | 6 | 22 |
2015 | 11 | 4 | 15 |
2016 | 6 | 2 | 8 |
2017 | 7 | 6 | 13 |
2018 | 7 | 8 | 15 |
2019 | 13 | 7 | 20 |
2020 | 9 | 8 | 17 |
2021 | 7 | 2 | 9 |
2022 | 3 | 1 | 4 |
2023 | 2 | 1 | 3 |
Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.
-
Implementing methods in the ELEGANCE registry to increase diversity in clinical research. J Vasc Surg. 2024 Jan; 79(1):136-145.e3.
-
Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation. Clin Pharmacol Ther. 2023 10; 114(4):815-824.
-
High-risk Therapeutic Devices Approved by the US Food and Drug Administration for Use in Children and Adolescents From 2016 to 2021. JAMA Pediatr. 2023 01 01; 177(1):98-100.
-
Post-Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004-2014. Clin Pharmacol Ther. 2022 Oct; 112(4):846-852.
-
The FDA and Ensuring Safety and Effectiveness of Devices, Biologics, and Technology. J Am Acad Orthop Surg. 2022 Jul 15; 30(14):658-667.
-
Reporting Device-Associated Death Events to the FDA-Reply. JAMA Intern Med. 2022 04 01; 182(4):462-463.
-
New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence. Drug Saf. 2022 04; 45(4):305-318.
-
Renewing the Call for Reforms to Medical Device Safety-The Case of Penumbra. JAMA Intern Med. 2022 01 01; 182(1):59-65.
-
Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms. JAMA Intern Med. 2021 10 01; 181(10):1275-1276.
-
Post-market surveillance of consumer products: Framework for adverse event management. Regul Toxicol Pharmacol. 2021 Nov; 126:105028.